On ECHEMI
Home > Drugs > Gum cancer
Gum cancer
Cancer is the most common malignant tumor in the oral and maxillofacial region, and squamous cell carcinoma is the most common cancer. In my country, oral and maxillofacial squamous cell carcinoma mostly occurs between the ages of 40 and 60, and is more common in men than in women. Gingival cancer, tongue cancer, cheek cancer, palate cancer, and maxillary sinus cancer are common. Oral cancer accounts for 1.45-5.6% of all malignant tumors in the north of the Yangtze River in my country, and 1.75-5.18% in the south of the Yangtze River. In India, it accounts for more than 40% of all malignant tumors in the body. According to the degree of pathological differentiation, squamous cell carcinoma can generally be divided into grade III: grade I is highly differentiated and has a low degree of malignancy; grade III is poorly differentiated and has a high degree of malignancy; undifferentiated cancer has the highest degree of malignancy. The incidence of gingival cancer in my country is relatively high. According to statistics from Shanghai Second Medical University, it ranks first in the composition ratio of malignant tumors, and most of them are highly differentiated squamous cell carcinomas.
  • Site of disease:

    mouth
  • Infectious :

    Not contagious
  • Frequent population:

    Occurs between the ages of 40 and 60, mostly in men...
  • Related symptoms:

    Pad redness and swelling after molars Pain when teeth erupt Difficulty opening the mouth Wounds that do not heal after tooth extraction Bone destruction
  • Concurrent disease:

Related Drugs
Ice Boron Lozenges
Manufacturer:

Xi'an Jiaotong University Pharmaceutical (Group) Co., Ltd.

Furfuryl sterol tablets
Indication: Used for periodontal abscess, bleeding gums and other dental diseases.
Manufacturer:

Betta Pharmaceuticals Co., Ltd.

Related Ingredients
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.